This application describes a randomized controlled clinical trail to evaluate the efficacy of a brief, standardized cognitive psychotherapy, Problem Solving Therapy (PST), to prevent incident depressive disorder (DSM-IV diagnoses) in elderly patients with age-related macular degeneration (AMD). AMD is the most common cause of blindness in older adults and limits the ability to read, see familiar faces, and walk independently. Almost 2 million persons (about 5 percent of the U.S. population over age 65) are now affected and their number will triple by the year 2020. We will target patients with neovascular AMD (NV-AMD), a form of AMD that can lead to sudden vision loss, substantial disability, and depression. Because depression is itself disabling and not likely to be recognized nor treated by ophthalmologists, preventing depression is clearly important. We will recruit 230 non-depressed AMD patients from the retinovascular clinic of Wills Eye Hospital with newly diagnosed NV-AMD one eye, who already have AMD in the fellow eye. Because they have recently developed bilateral vision loss they will be at high risk for depression. We will randomize subjects to PST or a usual care control condition in this 6-month clinical trial. The primary outcome measure will be a DSM-IV diagnosis of depression diagnosed by a geriatric psychiatrist masked to treatment assignment. We will evaluate subjects at baseline, month 2 (immediately post-intervention), month 6 (for the primary efficacy analysis) and month 12 (to evaluate sustained effects). Although depressive disorder is the primary outcome, we will also assess the impact of PST on levels of disability and vision-related quality of life.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH061331-05
Application #
6848777
Study Section
Special Emphasis Panel (ZRG1-RPHB-3 (01))
Program Officer
Niederehe, George T
Project Start
2001-02-06
Project End
2006-01-31
Budget Start
2005-02-23
Budget End
2006-01-31
Support Year
5
Fiscal Year
2005
Total Cost
$184,271
Indirect Cost
Name
Thomas Jefferson University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Rovner, Barry W; Casten, Robin J; Leiby, Benjamin E (2009) Variability in depressive symptoms predicts cognitive decline in age-related macular degeneration. Am J Geriatr Psychiatry 17:574-81
Rovner, Barry W; Casten, Robin J; Leiby, Benjamin E et al. (2009) Activity loss is associated with cognitive decline in age-related macular degeneration. Alzheimers Dement 5:12-7
Casten, Robin; Rovner, Barry (2008) Depression in Age-Related Macular Degeneration. J Vis Impair Blind 102:591-599
Rovner, Barry W; Casten, Robin J (2008) Preventing late-life depression in age-related macular degeneration. Am J Geriatr Psychiatry 16:454-9
Rovner, Barry W; Casten, Robin J; Hegel, Mark T et al. (2007) Preventing depression in age-related macular degeneration. Arch Gen Psychiatry 64:886-92
Rovner, Barry W; Casten, Robin J; Hegel, Mark T et al. (2007) Dissatisfaction with performance of valued activities predicts depression in age-related macular degeneration. Int J Geriatr Psychiatry 22:789-93
Whyte, Ellen M; Rovner, Barry (2006) Depression in late-life: shifting the paradigm from treatment to prevention. Int J Geriatr Psychiatry 21:746-51
Rovner, Barry W; Casten, Robin J; Hegel, Mark T et al. (2006) Minimal depression and vision function in age-related macular degeneration. Ophthalmology 113:1743-7
Rovner, Barry W; Casten, Robin (2005) Stability of visual acuity measurement in depression. Am J Geriatr Psychiatry 13:255-8
Rovner, Barry W; Casten, Robin J; Tasman, William S (2002) Effect of depression on vision function in age-related macular degeneration. Arch Ophthalmol 120:1041-4